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Haloperidol prophylaxis in critically ill patients
with a high risk for delirium
Mark van den Boogaard1*, Lisette Schoonhoven2,3, Theo van Achterberg2, Johannes G van der Hoeven1,4 and
Peter Pickkers1,4
Abstract
Introduction: Delirium is associated with increased morbidity and mortality. We implemented a delirium
prevention policy in intensive care unit (ICU) patients with a high risk of developing delirium, and evaluated if our
policy resulted in quality improvement of relevant delirium outcome measures.
Methods: This study was a before/after evaluation of a delirium prevention project using prophylactic treatment
with haloperidol. Patients with a predicted risk for delirium of ≥ 50%, or with a history of alcohol abuse or
dementia, were identified. According to the prevention protocol these patients received haloperidol 1 mg/8 h.
Evaluation was primarily focused on delirium incidence, delirium free days without coma and 28-day mortality.
Results of prophylactic treatment were compared with a historical control group and a contemporary group that
did not receive haloperidol prophylaxis mainly due to non-compliance to the protocol mostly during the
implementation phase.
Results: In 12 months, 177 patients received haloperidol prophylaxis. Except for sepsis, patient characteristics were
comparable between the prevention and the historical (n = 299) groups. Predicted chance to develop delirium
was 75 ± 19% and 73 ± 22%, respectively. Haloperidol prophylaxis resulted in a lower delirium incidence (65% vs.
75%, P = 0.01), and more delirium-free-days (median 20 days (IQR 8 to 27) vs. median 13 days (3 to 27), P = 0.003)
in the intervention group compared to the control group. Cox-regression analysis adjusted for sepsis showed a
hazard rate of 0.80 (95% confidence interval 0.66 to 0.98) for 28-day mortality. Beneficial effects of haloperidol
appeared most pronounced in the patients with the highest risk for delirium. Furthermore, haloperidol prophylaxis
resulted in less ICU re-admissions (11% vs. 18%, P = 0.03) and unplanned removal of tubes/lines (12% vs. 19%, P =
0.02). Haloperidol was stopped in 12 patients because of QTc-time prolongation (n = 9), renal failure (n = 1) or
suspected neurological side-effects (n = 2). No other side-effects were reported. Patients who were not treated
during the intervention period (n = 59) showed similar results compared to the untreated historical control group.
Conclusions: Our evaluation study suggests that prophylactic treatment with low dose haloperidol in critically ill
patients with a high risk for delirium probably has beneficial effects. These results warrant confirmation in a
randomized controlled trial.
Trial registration: clinicaltrial.gov Identifier: NCT01187667.
Introduction
Delirium is a neuropsychiatric disorder characterized by
an acute onset of confusion and consciousness altera-
tions that fluctuate during the day [1]. The incidence of
delirium in intensive care (ICU) patients is high [2-5],
up to 80%, and its occurrence is associated with pro-
longed duration of mechanical ventilation, increased
ICU- and hospital length of stay [3,5], unplanned
removal of tubes and catheters [5] and an increased
mortality [5,6]. Therefore, preventive treatment for delir-
ium may be beneficial. In non-ICU patients beneficial
effects of prophylactic haloperidol in older [7] and surgi-
cal ICU patients [8] have been reported. For critically ill
patients, data concerning preventive treatment are
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scarce and inconsistent [7,9-11]. Only prophylactic treat-
ment with the anti-psychotic drug haloperidol seems to
have some beneficial effects in ICU patients [12].
In one retrospective cohort study, ICU patients treated
with haloperidol appeared to have a lower mortality rate
compared to non-treated ICU patients [13]. Another
recent study showed that haloperidol prophylaxis in non-
cardiac surgical ICU patients had beneficial effects on
delirium incidence and delirium free days [12]. Note-
worthy, in this study no delirium risk stratification was
performed, suggesting that the beneficial effects might be
diluted in the whole group of ICU patients and that more
pronounced effects may be present in patients with a
high risk to develop delirium. Preventive treatment of all
ICU patients may not only dilute the potential beneficial
effects of haloperidol, but also exposes a substantial num-
ber of patients to unnecessary potential risks, for exam-
ple, the side-effects of haloperidol administration. With
the use of a recently developed and validated delirium
prediction model for ICU patients [14], patients with a
high risk of developing delirium can be identified and tar-
geted preventive treatment becomes possible. In view of
the high incidence of delirium, the impact of delirium on
outcome and the availability of a delirium prediction
model to identify high risk ICU patients, we implemented
a delirium prevention protocol in our clinical practice
using a low dosage of haloperidol. The aim of this study
was to evaluate if our policy resulted in quality improve-
ment of relevant delirium outcome measures.
Material and methods
Design and setting
When the decision to implement the delirium prevention
protocol was taken, it was prospectively decided to evalu-
ate its effects after one year. A before/after evaluation of
a delirium prevention protocol was carried out in our 33-
bed intensive care unit (ICU) of the Radboud University
Nijmegen Medical Centre, The Netherlands. We wanted
to evaluate if our changed delirium policy resulted in
improvement of delirium outcome in daily practice. It is
recommended to evaluate important changes in daily
practice and, according to Dutch law, no approval from
an Ethics Committee is warranted when a change in
medical policy is evaluated. Nevertheless, we informed
our Ethics Committee about the change in policy and the
planned analysis upon which it was agreed. This evalua-
tion study was registered in the Clinical trial register
(NCT01187667).
Patients
All consecutive ICU patients admitted to our intensive
care unit between 1 August 2010 and 1 August 2011
were screened for delirium risk and patients with a high
risk for delirium (PREdiction DELIRium Intensive Care
(PREDELIRIC) score >50% [14], diagnosis of dementia,
or alcohol abuse as mentioned in the medical history of
the patient) received haloperidol prophylaxis. Following
discussion in the ICU staff we defined high risk for delir-
ium as having a PREDELIRIC score [14] of 50% or more.
Patients in whom the haloperidol dosage was adjusted or
the haloperidol was stopped were for this evaluation allo-
cated to the intervention group. To evaluate the effects of
this prevention policy, it was decided beforehand to com-
pare the results with a control group of high risk ICU
patients admitted between 1 February 2008 and 1 Febru-
ary 2009 and with a contemporary group of patients who
did not receive prophylactic treatment for various rea-
sons (Figure 1) during the intervention period. Also, an
additional analysis to determine which delirium risk sub-
group (’low, middle, high’) within the high risk patients
benefitted most from the prophylactic therapy was part
of our prospectively agreed analysis plan. Patients in the
control group were only treated for delirium and treat-
ment with haloperidol was started as soon as possible
after delirium was diagnosed according to our delirium
protocol. Patients in the control group and in the inter-
vention were treated at the same ICU location; there
were no alterations in environmental conditions during
the duration of the study.
Delirium assessment
All patients were screened by well-trained ICU nurses
[15] using the Dutch version of the CAM-ICU [16] at
least three times daily, and more often if required. The
CAM-ICU screening compliance in the control group
was 90.4% and in the intervention group, 94.5%.
To secure the quality of the delirium diagnosis, medical
and nursing files of all patients were also screened daily
for signs of delirium [17]. When the files contained signs
of delirium without a positive CAM-ICU screening or
conversely, patients were additionally screened by a delir-
ium expert serving as the ‘gold standard’, [1] to rule out
false negatives and positives. Related to another delirium
study [18] we performed these above mentioned additional
checks in the historical group as well as in the intervention
group.
Patients were excluded when it was impossible to
assess the patient for the presence of delirium using the
CAM-ICU, that is, because of coma during the entire
ICU stay, serious auditory or visual disorders, inability to
understand Dutch, severe mental disability or the pre-
sence of receptive aphasia. Patients with delirium were
divided into three subtypes [19] as measured during the
complete delirium period: hyperactive (Richmond agita-
tion sedation score (RASS) [20] +1/+4), hypoactive
(RASS 0/-3), and mixed (RASS +4/-3). This last subtype
of delirium is characterized by alternating symptoms of
hyperactive and hypoactive delirium. Patients were
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diagnosed with delirium when they had at least one posi-
tive CAM-ICU screening during their complete ICU stay.
A delirium-and-coma-free day was defined as a negative
CAM-ICU screening without RASS -4/-5 during a com-
plete day. Follow-up of all patients was conducted
prospectively.
Delirium prevention
In August 2010 the delirium prevention policy was imple-
mented in daily practice. Patients with an estimated risk of
50% or more determined with the delirium prediction
model PRE-DELIRIC [14] and patients with a history of
diagnosed dementia or alcohol abuse were considered
high risk. The PRE-DELIRIC model is a recently devel-
oped and validated delirium prediction model for ICU
patients with a high predictive value and consists of 10
predictors, such as age, Acute Physiology and Chronic
Health Evaluation II (APACHE-II) score, infection, non-
sustained coma, use of sedatives and so on. These predic-
tors are readily available within 24 hours after ICU admis-
sion and predict the risk of developing a delirious episode
during the complete ICU stay. These high-risk patients
received intravenous haloperidol 1 mg/8 h or a lower dose
of 0.5 mg/8 h when they were ≥ 80 years, had a body
weight <50 kg, had a serum creatinine level >150 μmol/L
or had a serum bilirubin level >50 μmol/L. Intravenous
haloperidol prophylaxis was started as soon as it was clear
when patients had an increased risk, ranging from imme-
diately following ICU admission to 24 hours after ICU
admission. If prophylactic therapy was not started within
four hours following identification of a high risk patient
(24 hours after ICU admission), prophylactic treatment
was considered ‘too late’ and this patient was excluded
from the prophylaxis group. In comatose patients, halo-
peridol was also started; however, if this condition lasted
for longer than three days then haloperidol was tempora-
rily stopped until recovery of consciousness. No other
anti-psychotics were administered. Patients who developed
delirium received therapeutic doses of haloperidol accord-
ing to the department’s protocol.
According to the protocol, prevention was not started
when haloperidol was contraindicated in the case of Par-
kinson’s disease, hypokinetic rigid syndrome, Lewy body
dementia, prolonged QTc-time of over 500 msec, preg-
nancy or in patients who were treated with other anti-
psychotics.
Since no other changes in the delirium protocol, as well
as in other relevant protocols (that is, sedation and pain)
were made during the evaluation period, patients in the
control group received, except for the haloperidol prophy-
laxis, the same treatment compared with the delirium pre-
vention group.
Figure 1 Flowchart of inclusion of high risk ICU patients.
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Outcome measures
For this evaluation, primary outcome measures were
delirium incidence, number of days alive without delir-
ium and without coma in a period of 28 days, and 28-
day mortality. Secondary outcomes were duration of
mechanical ventilation, incidence of re-intubation and
re-admissions, incidence of unplanned removal of tubes/
catheters and ICU- and hospital-length-of-stay. Apart
from the analysis of the complete prevention and con-
trol group, patients were divided into subgroups based
on their predicted chance of developing delirium, to
investigate which subgroup of patients benefits most
from prophylactic treatment with haloperidol. We also
studied outcome in four different admission categories,
that is, surgical, medical, trauma and neurological or
neurosurgical patients.
Since 2007 delirium has been one of the research
topics in our ICU [15], and several delirium related
measures have been collected prospectively, with the
exception of the PREDELIRIC scores. These were only
available for the described control period, as the delir-
ium prediction model was developed in that period.
Statistical analyses
Demographic characteristics of patients who received
haloperidol prophylaxis were compared with non-treated
patients. Differences were tested with Student’s t-test,
Mann-Whitney U test or with the Chi-square test,
depending on their distribution. Survival analyses with
Kaplan-Meier curves as graphical presentation were used.
Beforehand it was decided to adjust for variables which
differ significantly between the two groups. This decision
was based on the fact that the only patients included
were those with an increased delirium risk using the
PREDELIRIC model consisting of 10 predictors [14].
Therefore, not only the delirium risk should be about
equal between the two groups, but also other relevant
variables which are part of this prediction model.
To determine the effect of haloperidol on 28-day mortal-
ity adjusted for covariates, we used Cox proportional
hazard regression analysis with mortality as the dependent
variable and baseline characteristics with a P-value <0.05
between groups as possible covariates. In case of multicolli-
nearity, determined using Spearman’s rho (P-value <0.05),
the covariate which best associated with the outcome vari-
able mortality was included in the Cox-regression analysis.
To examine which patients were most likely to benefit, we
equally divided the total group into three risk groups
(predicted risk up to 71%, between 71 and 89% and >89%).
This distribution was made using the SPSS function ‘Visual
binning’ resulting in an independent optimal distribution
in three subgroups. Patient characteristics that differed
between groups served as covariates. Statistical significance
was defined as a P-value <0.05. All data were analyzed
using SPSS version 18.0 (SPSS, Chicago, IL, USA).
Results
During the intervention period (2010 to 2011), 2,320
consecutive ICU patients were screened and 320 patients
fulfilled the inclusion criteria for delirium prevention. In
the control group (2008 to 2009), 2,132 consecutive ICU
patients were screened, of which 432 patients met the
inclusion criteria. In the intervention period, a total of
143 patients were excluded and in the control group 133
patients (Figure 1). Overall, 177 patients in the interven-
tion group and 299 patients in the control group were
evaluated. Patient and demographic characteristics are
shown in Table 1. In the intervention group patients
tended to have a slightly lower APACHE-II score, and
significantly more patients were admitted with sepsis
compared with the control group (P = 0.02). Twenty-two
(12%) patients in the intervention and 46 (15%) patients
in the control group were enrolled because of alcohol
abuse or dementia.
Primary outcomes
The predicted chance of developing delirium in the
intervention and control group was 75 ± 19% and 73 ±
22%, respectively (P = 0.50). The actual delirium inci-
dence was 65% in the intervention group, compared
with 75% in the control group (P = 0.01) (Table 2). The
number of delirium free days was significantly higher in
the intervention group (median 20 days (interquartile
range 8 to 27) versus median 13 days (3 to 27) (P =
0.003)). Cox proportional hazard regression analysis was
performed with sepsis as a covariate. Prophylactic treat-
ment with haloperidol resulted in a relative 28-day mor-
tality reduction of 20% (hazard rate 0.80; 95% CI 0.66 to
0.98). Figure 2 shows the 28-day Kaplan-Meier survival
curve of both groups. Since multicollinearity was deter-
mined between sepsis and the APACHE-II score (bor-
derline significant difference between the two groups)
we used only sepsis as a covariate.
Secondary outcomes
No significant differences were found between groups in
duration of mechanical ventilation, ICU- and hospital-
length-of-stay, and incidence of re-intubation. Patients
who received prophylaxis were less likely to remove
their tubes and catheters (P = 0.02) and were less likely
to be re-admitted to the ICU (P = 0.03) (Table 2).
Risk groups and admission categories
To examine which patients benefit most from the prophy-
lactic therapy with haloperidol, the total group was equally
divided into three groups based on their predicted risk.
van den Boogaard et al. Critical Care 2013, 17:R9
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Table 1 Demographic and patients characteristics
Control
group
(N = 299)
Intervention group
(N = 177)
Differences
(P-value)
Male (n/%) 181 (61%) 115 (65%) 0.20
Age 64 ± 14 63 ± 14 0.64
APACHE-II score 20 ± 7 19 ± 6 0.06
Urgent admission (%) 261 (87%) 152 (86%) 0.52
Sedation level (RASS, median (IQR))
- RASS screening compliance (%)
-1 (-3 to 0)
93.3 ± 1.2
-1 (-3 to 0)
94.5 ± 0.9
0.84
Haloperidol administering
- Number of treated patients (%) 225 (75.3%) 177 (100%) <0.0001
- Number of treated days 5 (2 to 12) 5 (3 to 11)* 0.23
- Dosage (mg per day) median ((IQR)) 6 (3 to 10) 2 (2 to 3) <0.0001
Sepsis (N/%) 64 (21%) 53 (30%) 0.02
Admission specialism (N/%):
- Surgical 75 (25%) 33 (19%) 0.18
- Medical 143 (48%) 106 (60%) 0.12
- Trauma 32 (11%) 18 (10%) 0.27
- Neurology/neurosurgical 49 (16%) 20 (11%) 0.36
PRE-DELIRIC score 73 ± 22 75 ± 19 0.50
Other risk
- Alcohol abuse 41 (14%) 20 (11%) 0.37
- Dementia 5 (2%) 2 (1%)
* Including prophylactic days of treatment. Data are presented as mean ± standard deviation unless mentioned otherwise.
Table 2 Differences between control group and complete intervention group
Control
group
(N = 299)
Intervention group
(N = 177)
Differences
(P-value)
Predicted delirium chance 73 ± 22 75 ± 19 0.50
Observed delirium incidence (n,%) 225 (75%) 115 (65%) 0.01
Non-delirium: 74 (25%) 62 (35%) 0.38
Delirium subtype:
- Hyperactive 20 (7%) 6 (3%)
- Hypoactive 81 (27%) 33 (19%)
- Mixed 124 (41%) 76 (43%)
Number of delirium free days without coma in 28 days 13 (3 to 27) 20 (8 to 27) 0.003
Re-intubation (%) 25 (8%) 15 (9%) 0.51
Duration mechanical ventilation in hrs. 118 (39 to 250) 90 (36 to 229) 0.24
Unplanned removal tubes/lines (%) 58 (19%) 21 (12%) 0.02
- Tube 8 (3%) 4 (2%)
- Gastric tube 26 (9%) 14 (8%)
- CVC/arterial line 24 (8%) 1 (<1%)
- Other 0 (0%) 2 (1%)
Re-admission 55 (18%) 20 (11%) 0.03
LOS-ICU 7 (3 to 13) 6 (3 to 12) 0.65
LOS-in hospital 21 (12 to 41) 20 (11 to 31) 0.16
28-day mortality 36 (12%) 13 (7.3%) 0.03*
Data are presented as median, interquartile range (IQR), unless mentioned otherwise. * Cox proportional hazard regression analysis adjusted for sepsis and cohort
(hazard rate 0.80; 95% CI 0.66 to 0.98.
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Patients with the highest risk appear to benefit most from
the prophylactic treatment with haloperidol (Table 3),
although no statistically significant difference between
groups was reached for all end points.
Results of prophylactic haloperidol treatment for the
different admission categories are shown in Appendix A
(Additional file 1). The beneficial effects of prophylactic
treatment were comparable between patient groups.
Medical patients appeared to benefit most from prophy-
lactic haloperidol treatment.
Non-treated patients during the implementation period
During the implementation period, a total of 59 patients
did not receive prophylaxis with haloperidol, mostly due
to non-compliance to the new protocol in the early phase
of implementation. There were no demographic differ-
ences between the control group and this non-treated
group (Table 4). However, there were significantly more
patients with sepsis in the non-treated intervention
group compared with the control group. Also, there was
a small, non-significant difference in case-mix among the
three groups.
The incidence of delirium, unplanned removal of
tubes and re-admission rate was significantly higher and
the number of delirium free days was significantly lower
in the non-treated group compared with the treated
intervention group. In addition, the delirium incidence
in the non-treated intervention group was also signifi-
cantly higher compared with the treated intervention
group (Table 4).
Haloperidol treatment
All patients were examined daily for signs of rigidity, rest-
lessness, Parkinsonism, QTc-time measurement and level
of sedation. In 14 out of 177 (8%) patients, adjustments in
dosage were made because of possible side effects, with
drowsiness as the most frequently mentioned reason (6%).
Haloperidol was stopped in 12 (7%) patients because of
prolonged QTc-time (n = 9, all in patients treated with
mild hypothermia), signs of Parkinsonism (n = 1), renal
failure (n = 1) and in one patient malignant neuroleptic
syndrome was suspected, but later not confirmed. Impor-
tantly, none of the nine patients developed any tachyar-
rhythmia during the prolonged QTc-time period.
Figure 2 Kaplan-Meier survival plot of 28-day survival.
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Table 3 Differences between control group and complete intervention group divided in three delirium risk groups
Predicted chance <71% Control group
(N = 110)
Intervention group (N = 69) Differences
(P-value)
Predicted chance 50 ± 19 55 ± 16 0.08
Age 63 ± 13 63 ± 14 0.88
APACHE-II score 17 ± 5 16 ± 5 0.12
Sepsis (%) 11 (10%) 18 (26%) 0.005
Observed delirium incidence 55 (50%) 30 (44%) 0.27
28 days delirium free without coma 26 (10 to 28) 26 (13 to 28) 0.17
28-day mortality 13 (12%) 6 (9%) 0.34*
Re-intubation (%) 5 (5%) 6 (9%) 0.25
Duration mechanical ventilation in hrs. 42 (14 to 150) 63 (15 to 168) 0.43
Unplanned removal tubes/lines (%) 14 (13%) 7 (10%) 0.41
- Tube 1 (1%) 1 (2%)
- Gastric tube 2 (2%) 4 (6%)
- CVC/arterial line 11(10%) 1 (2%)
- Other 0 (0%) 1 (<1%)
Re-admission 18 (16%) 4 (6%) 0.03
LOS-ICU 3 (2 to 8) 4 (2 to 8) 0.32
LOS-in hospital 17 (9 to 31) 16 (8 to 27) 0.48
Predicted chance 71 to 89% (N = 111) (N = 60) Differences
Predicted chance 81 ± 5 80 ± 5 0.66
Age 64 ± 14 61 ± 15 0.14
APACHE-II score 20 ± 6 20 ± 7 0.94
Sepsis (%) 31 (28%) 24 (40%) 0.08
Observed delirium incidence 94 (85%) 44 (73%) 0.06
28 days delirium free without coma 11 (3 to 22) 20 (7 to 27) 0.02
28-day mortality 13 (12%) 5 (8%) 0.93
Re-intubation (%) 11 (11%) 6 (10%) 0.56
Duration mechanical ventilation in hrs. 124 (55 to 278) 133 (50 to 281) 0.76
Unplanned removal tubes/lines (%) 22 (20%) 8 (13%) 0.20
- Tube 4 (4%) 2 (3%)
- Gastric tube 12 (11%) 6 (10%)
- CVC/arterial line 6 (5%) 0 (0%)
Re-admission 27 (24%) 12 (20%) 0.33
LOS-ICU 8 (3 to 15) 8 (4 to 17) 0.57
LOS-in hospital 23 (13 to 43) 26 (16 to 41) 0.99
Predicted chance >89% (N = 78) (N = 48) Differences
Predicted chance 95 ± 3 95 ± 3 0.95
Age 62 ± 16 65 ± 12 0.34
APACHE-II score 24 ± 8 21 ± 6 0.05
Sepsis (%) 22 (28%) 11(23%) 0.33
Observed delirium incidence 76 (97%) 41 (85%) 0.06
28 days delirium free without coma 4 (0 to 14) 13 (6 to 21) 0.002
28-day mortality 10 (13%) 2 (4%) 0.07†
Re-intubation (%) 9 (12%) 3 (6%) 0.25
Duration mechanical ventilation in hrs. 185 (112 to 353) 94 (62 to 266) 0.02
Unplanned removal tubes/lines (%) 22 (28%) 6 (13%) 0.04
- Tube 3 (4%) 1 (2%)
- Gastric tube 12 (15%) 3 (6%)
- CVC/arterial line 7 (9%) 0 (0%)
- Other 0 (0%) 2 (4%)
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Discussion
This before/after evaluation study suggests that prophy-
lactic treatment with haloperidol in ICU patients with a
high risk for delirium results in a lower delirium inci-
dence, more delirium free days and a reduction in mor-
tality. In addition, the evaluation of our delirium
prevention policy shows that patients that received pro-
phylactic haloperidol were less likely to remove their
tubes or catheters or to be readmitted to the ICU, also
illustrating the beneficial effects of prophylactic therapy
with haloperidol. Importantly, only a few side-effects of
low dose haloperidol were reported of which none were
severe. The results of our evaluation study need to be
confirmed in a study with a more powerful design.
Although our study design is not optimal, our results
are in accordance with previous studies in which pro-
phylactic treatment with haloperidol was successfully
used in older and surgical patients [8] and recently in a
group of non-cardiac surgical ICU patients [12].
While prophylactic therapy for delirium is sparsely stu-
died in critically ill patients, more data are available con-
cerning the treatment of delirium in hospitalized
patients. Haloperidol is recommended as the first choice
drug for delirium treatment [1,21-23]. Several studies
showed that use of other anti-delirium drugs than halo-
peridol [24-26] do not further improve patient outcome,
but could even worsen it [27]. However, one small study
showed that the use of other anti-delirium drugs in com-
bination with haloperidol improved delirium outcome
[28]. Some of these randomized trials demonstrated less
Table 4 Non-treated patients in the intervention group compared with treated and control group
Control
group
(N = 299)
Intervention group
non-treated
(N = 59)
Intervention group
treated
(N = 177)
PRE-DELIRIC score (mean ± sd) 73 ± 22 77 ± 17 75 ± 19
Other risk
- Alcohol abuse 41 (14%) 4 (7%) 20 (11%)
- Dementia 5 (2%) 0 2 (1%)
Age (mean ±) 64 ± 14 62 ± 15 63 ± 14
Urgent admission (%) 261 (87%) 52 (88%) 152 (86%)
APACHE-II score 20 ± 7 20 ± 6 19 ± 6
Sepsis (%) 64 (21%)b 16 (28%)a 53 (30%)a
Gender (M/%) 181 (61%) 35 (59%) 115 (65%)
Admission specialism (N/%):
- Surgical 75 (25%) 11 (19%) 33 (19%)
- Medical 143 (48%) 30 (51%) 106 (60%)
- Trauma 32 (11%) 5 (9%) 18 (10%)
- Neurology/neurosurgical 49 (16%) 13 (22%)c 20 (11%)
Delirium incidence 225 (75%)b 53 (90%)a-b 115 (65%)
28 days delirium free without coma 13 (3 to 27)b 14 (1 to 22)b 20 (8 to 27)
28-day mortality 36 (12%)b 7 (12%) 13 (7%)
Re-intubation (%) 25 (8%) 8 (14%) 15 (9%)
Duration mechanical ventilation in hrs. 118 (39 to 250) 103 (54 to 251) 90 (36 to 229)
Unplanned removal tubes/lines (%) 58 (19%)b 13 (22%)b 21 (12%)
Re-admission 55 (18%)b 13 (22%)b 20 (11%)
LOS-ICU 7 (3 to 13) 7 (4 to 14) 6 (3 to 12)
LOS-in hospital 21 (12 to 41) 27 (13 to 48)b 20 (11 to 31)
Data are presented as median, interquartile range (IQR), unless mentioned otherwise. a Statistically significantly different (P <0.05) compared with control group. b
Statistically significantly different (P <0.05) compared with treated intervention group. c Borderline significant difference between non-treated and treated
intervention group (P = 0.057).
Table 3 Differences between control group and complete intervention group divided in three delirium risk groups
(Continued)
Re-admission 10 (13%) 4 (8%) 0.32
LOS-ICU 11 (7 to 18) 6 (4 to 15) 0.03
LOS-in hospital 30 (14 to 56) 20 (15 to 31) 0.07
Data are presented as median, interquartile range (IQR), unless mentioned otherwise. * Cox proportional hazard regression analysis with sepsis as covariate. † Cox
proportional hazard regression analysis with APACHE-II score as covariate.
van den Boogaard et al. Critical Care 2013, 17:R9
http://ccforum.com/content/17/1/R9
Page 8 of 11
severe or shorter duration of delirium in the treatment
groups, but were underpowered to detect an effect on
length of stay or mortality [24-26]. In an observational
study, a lower mortality rate in ICU patients was
observed in ICU patients treated with haloperidol com-
pared to those that were not treated [13]. In addition,
observational data also suggest that early treatment of
delirium results in a lower mortality rate compared with
delayed treatment [29]. How haloperidol decreases mor-
tality is unknown. Knowing the energy consuming nature
of delirium, it appears plausible that patients suffering
from delirium become exhausted, eventually resulting in
respiratory insufficiency. The higher incidence of re-intu-
bations, ICU readmissions and diversion of the Kaplan-
Meier curves from Day 10 are in accordance with this
assumption. These data indicate that the effectiveness of
early treatment, or possibly even better prophylaxis, may
be superior compared to treatment of delirium. However,
prophylactic treatment of all ICU patients inherently
results in a number of patients who are unnecessarily
exposed to the side-effects of haloperidol, which may
harm the patient [30]. In the study of Wang et al. [12], all
non-cardiac surgical ICU patients were included irrespec-
tive of their level of risk, indicating that overtreatment
occurred. Furthermore, this may have diluted the pro-
phylactic effect of haloperidol in the patients with a high
chance of developing delirium. Therefore, there is a need
for a delirium prediction model for ICU patients, which
identifies the patients with a high risk of developing delir-
ium. In the present study, we used our delirium predic-
tion model with a high predictive value [14]. Importantly,
our data suggest that the higher the predicted risk, the
more effective prophylaxis with haloperidol is. Also, it
seems that medical patients benefit more than surgical
patients, which may be due to the higher delirium risk in
these patients, or the differences in the underlying
mechanism of delirium.
Several limitations need to be addressed. Most impor-
tantly, we performed a before/after evaluation study
instead of a more powerful and controlled design, such as
a randomized controlled trial. Nevertheless, the fact that a
better outcome was observed in patients that received pro-
phylactic haloperidol also compared to non-prophylacti-
cally treated patients during the intervention period, could
indicate that the results were not relevantly confounded
by a time-dependent bias. In addition, we chose relevant
end-points known to be related to delirium. In view of the
congruent effects of prophylactic treatment with haloperi-
dol on several end points, the plausibility of our findings is
further supported. Importantly, during the complete study
there were no important changes in medical policy con-
cerning analgesia as well as for sedation, illustrated by
similar RASS scores in the two groups. Therefore, it
appears unlikely that time-dependent bias played an
important role in our study. However, we appreciate that
this observational retrospective cohort study, including a
contemporary cohort, is not an optimal design to draw
firm conclusions. Therefore, a randomized controlled trial
is necessary to confirm our conclusions.
Second, we did not use the ‘gold standard’, the DSM-IV
criteria [1], to diagnose delirium in daily ICU practice,
but we used the CAM-ICU of which it was recently
determined the performance is somewhat lower [31,32]
than in the original studies of Ely et al. [31-34]. Impor-
tantly, in view of the fluctuating nature of delirium, all
patients were screened three times daily and more often
if needed. When delirium was not detected with the
CAM-ICU, but delirium was suspected based on medical
and nursing reports, patients were additionally screened
by a delirium expert according to the DSM-IV criteria.
Furthermore, in a previous study we determined that the
inter-rater reliability of the CAM-ICU screenings by our
ICU nurses was high [15]. We, therefore, assume that
only a few patients may be misdiagnosed, which is likely
equally distributed between the study periods.
Third, potential side-effects of haloperidol were only
observed when spontaneously reported and mild extra-
pyramidal side-effects may have been missed, although
daily thorough physical examination of all patients is the
usual care in our ICU. Regarding QTc-time, this was
measured daily using an electrocardiogram (ECG). In
nine patients haloperidol was stopped because of pro-
longed QTc-time, which was probably due to the
immediate start of haloperidol in the post-cardiopul-
monary resuscitation phase after ICU admission com-
bined with mild therapeutic hypothermia [35] in all nine
patients. Moreover, QTc-time was only marginally pro-
longed and none of these patients developed ventricular
arrhythmia, as reported in some case reports [36-39], or
other tachyarrhythmias. Furthermore, in several patients,
haloperidol dose was adjusted for reasons of drowsiness
or a possible sedative effect. Importantly, all these
patients were delirious and these symptoms may also
represent manifestations of delirium [1,19]. The low
incidence of side effects is in accordance with previous
studies [7,8,40,41].
Fourth, the choice of the haloperidol dose likely influ-
ences the treatment effect. Our dosage was lower than
the 5 mg/day that was used in surgery patients [8],
which also resulted in a reduction of the delirium inci-
dence. In view of the few reported side-effects of halo-
peridol in our study and the other ICU study [12], and
the still relatively high delirium incidence rate in ICU
patients that received prophylactic treatment, a higher
prophylactic dosage should be considered in future
research.
Lastly, patients who were not preventively treated
according to our delirium prevention protocol, mostly
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due to non-compliance, served as an additional control
group. Although this group showed similar patient char-
acteristics as the historical control group and the pro-
phylactic treated intervention group, the outcome
measures in this group were comparable with the histor-
ical control group. This supports the beneficial effects of
prophylactic treatment with haloperidol.
Conclusions
The use of the delirium prevention protocol seems to
result in improvement of several delirium outcome mea-
sures. Prophylactic treatment with low dose haloperidol
in critically ill patients with a high risk of delirium likely
appears to exert relevant beneficial effects. With the
encouraging results of the recent and present studies,
we feel that a randomized prospective intervention
study in ICU patients with a high risk for delirium using
prophylactic haloperidol should be conducted. It should
be considered, given the few side-effects of a low dose
haloperidol, to also investigate the effect of a higher pro-
phylactic dosage of haloperidol.
Key messages
• Identifying high risk with a delirium prediction
model (PREDELIRIC) facilitates targeted delirium
prevention.
• Low dosage of prophylactic haloperidol in ICU
patients with a high risk for delirium is associated
with a lower incidence of delirium, more delirium-
free days and a lower mortality.
• Also, complications related to delirium (for exam-
ple, unintended removal of lines and tubes) were
less frequent in patients that received prophylactic
treatment with haloperidol.
• Medical patients and those with the highest delir-
ium risk appear to benefit the most.
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